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ABSTRACT
Chimeric antigen receptor (CAR)-expressing T cells are a promising therapeutic 
option for patients with cancer. We developed a new CAR directed against the 
disialoganglioside GD2, a surface molecule expressed in neuroblastoma and in other 
neuroectoderm-derived neoplasms. The anti-GD2 single-chain variable fragment 
(scFv) derived from a murine antibody of IgM class was linked, via a human CD8a 
hinge-transmembrane domain, to the signaling domains of the costimulatory 
molecules 4–1BB (CD137) and CD3-ζ. The receptor was expressed in T lymphocytes 
by retroviral transduction and anti-tumor activities were assessed by targeting 
GD2-positive neuroblastoma cells using in vitro cytotoxicity assays and a xenograft 
model. Transduced T cells expressed high levels of anti-GD2 CAR and exerted a robust 
and specific anti-tumor activity in 4-and 48-hour cultures with neuroblastoma cells. 
Cytotoxicity was associated with the release of pro-apoptotic molecules such as TRAIL 
and IFN-γ. These results were confirmed in a xenograft model, where anti-GD2 CAR T 
cells infiltrating tumors and persisting into blood circulation induced massive apoptosis 
of neuroblastoma cells and completely abrogated tumor growth. This anti-GD2 CAR 
represents a powerful new tool to redirect T cells against GD2. The preclinical results 
of this study warrant clinical testing of this approach in neuroblastoma and other 
GD2-positive malignancies.
INTRODUCTION
Neuroblastoma is the most common extra-cranial 
solid tumor in young children, appearing at diagnosis 
in more than half of patients as metastatic disease [1]. 
Survival rates for patients with low and intermediate-risk 
neuroblastoma have progressively improved but the 
prognosis for those disseminated or high-risk diseases 
remains poor [2].
GD2 is a disialoganglioside highly expressed 
in several pediatric and adult cancers, including 
neuroblastoma [3, 4]. GD2 is expressed during fetal 
development but, among normal post-natal tissues, 
its expression is limited with low levels of expression 
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on osteoprogenitors, brain, peripheral nerves and 
skin melanocytes [5, 6]. Because of its high surface 
expression on tumor cells and low expression on normal 
tissues, GD2 has been a target for the development of 
immunotherapeutic monoclonal antibodies [7]. Starting 
from these encouraging clinical results, anti-GD2 antibody 
therapy is included in many frontline protocols for 
neuroblastoma [3, 8]. An alternative strategy to antibody 
therapy relies in incorporating the antibody specificity into 
a chimeric antigen receptor (CAR) and use this CAR to 
redirect T cells [9, 10]. In recent clinical trials, CAR T cells 
directed against CD19 have produced dramatic clinical 
responses in patients with B cell malignancies [11].
We generated a novel anti-GD2 CAR consisting 
of a mouse IgM derived anti-GD2 single-chain variable 
fragment (scFv) linked through the human CD8α 
hinge-transmembrane domain to a human portion of the 
4–1BB costimulatory molecule fused with the human 
CD3-ζ chain signaling domain. T cells carrying the 
anti-GD2 CAR were then tested against neuroblastoma 
cells in vitro and in vivo xenograft studies.
RESULTS
GD2 CAR retroviral vector retains significant 
transduction efficiency in T cells
The ectodomain of the CAR used in this study was 
a single-chain variable fragment (scFv) derived from a 
mouse IgM anti-GD2 MoAb in which heavy (VH) and light 
(VL) variable fragments were joined by 18 amino acids 
encoding the linker sequence, allowing the correct folding 
of the antigen binding site [12]. The scFv sequence was 
fused with the human CD8α derived hinge-transmembrane 
domain that connects to a signal transduction domain, 
consisting of 4-1BB and CD3-ζ (Fig. 1A). This CAR was 
expressed by a retroviral vector into human T cells.
To determine GD2 CAR expression in T cells, 
we generated anti-idiotypic antibodies specific for the 
anti-GD2 scFv. Immunized animal sera were obtained 
and titrated by flow cytometry on transduced FLYRD18 
cells known to retain high levels of transgene expression 
by GFP analyses. All obtained sera efficiently recognized 
GD2 CAR (Fig. 1B) on FLYRD18 surface and were 
therefore applied to detect GD2 CAR in the study and, as 
shown in Fig. 1C, GD2 CAR was significantly expressed 
after retroviral transduction on T cells.
Ex vivo stimulated T cells generated clusters 
with high proliferative capacity that started in the 
pre-stimulation phase (Fig. 1D, left panel) and was 
maintained after cell transduction (Fig. 1D, 2 representative 
donors in the middle and right panels). Gene modified 
T cells were expanded and further characterized by flow 
cytometry 15 days after gene transfer. Both GFP only 
T cells and GD2 CAR T cells were defined by a significant 
CD3+/CD8+ expansion rate representing the predominant 
T cell subset, followed by NK T cells expressing both 
CD3 and CD56. CD3-/CD56+/CD16+ NK cells persisted 
without significant enrichment throughout the culture 
(Fig. 2A, 2B).
GD2 CAR T cells exert specific in vitro 
cytotoxicity against neuroblastoma cells
SH-SY5Y and SKnBE target cell lines were assessed 
for their GD2 expression in order to be challenged by 
CAR T cell activity (Fig. 3). High GD2 expression was 
observed on SH-SY5Y, while low levels were detected on 
SKnBE. HeLa cell line showed undetectable GD2 levels 
and was used as negative control.
Once target cells selected, the specific cytotoxicity 
of unsorted GD2 CAR T cells (transduction efficiency of 
48 ± 2% by GFP expression) against neuroblastoma cell 
lines was first evaluated in a 4-hour 51Cr-release assay at 
E:T ratio of 20:1. GD2 CAR T cells showed significant 
higher cytotoxicity against SH-SY5Y cells as compared 
to that exerted by CAR-negative control T cells. There 
was no substantial difference in cytotoxicity between 
CAR-positive and CAR-negative T cells when the target 
cells were the GD2-low or negative cell lines SKnBE and 
HeLa, respectively (Fig. 4A). Confirming the observed 
cyotoxicity by 51Cr-release, calceinAM-based cytotoxicity 
assay revealed the specificity of the unsorted GD2 CAR 
T cells, even at unfavourable conditions such as 5:1 and 
10:1. As expected, there was not significant killing against 
the GD2 low SKnBE cells (Fig. 4B).
To further test the cytotoxic potential of GD2 CAR 
T cells, SH-SY5Y cells were cocultured for 48 hours 
with sorted GD2 CAR T cells at a lowest E:T ratio of 1:1 
(GD2 CAR T cell selection was performed by sorting 
GFP-positive cells). After 48 hours of coculture, cells 
were harvested to be analyzed by FACS and, again, GD2 
CAR T cells showed to exert a pronounced cytotoxicity 
(Fig. 4C). Moreover, the coculture of GD2 CAR T cells 
with SH-SY5Y cells induced a significant release of both 
IFNγ and TRAIL by the effector cells (Fig. 4D).
GD2 CAR T cells provide potent therapeutic 
activity in xenograft
In the next set of experiments, we assessed 
GD2 CAR T cell cytotoxicity in vivo. SH-SY5Y 
cells were injected subcutaneously in NOD/SCID 
mice that were then either injected locally with GD2 
CAR T cells or control T cells transduced with GFP 
only, while another group of mice did not receive 
T cells. Fig. 5A summarizes sequential tumor volume 
data. In the untreated group, all mice rapidly developed 
tumors that reached a mean volume over 1500 mm3 in 
less than 30 days. In mice treated by GFP only T cells, 
tumor development was observed in all mice but it was 
overall slower. In contrast, treatment with GD2 CAR 
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T cells suppressed tumor growth in all but one mouse. 
Harvested tumors (Figure 5B, first row) were then 
analysed by hematoxilin & eosin (Supplementary 
Figure 1) revealing a dramatic change in the histological 
architecture of specimens treated by GD2 CAR versus 
controls that displayed large areas containing densely 
populating neuroblastoma-like cells.
Immunohistochemical analyses of GFP were also 
performed and, shown in Figure 5B, clusters of infiltrating 
GFP positive cells were observed only in tumor sections 
taken from T cell treated animals (Figure 5B, second 
column) and were more prominent in the GD2 CAR 
treated group (Figure 5B, third column).
To detect GFP positive circulating T cells in treated 
mice and controls at the end of the study, DNA from 
peripheral blood was extracted and a sensitive RT-PCR 
targeting GFP was performed (Supplementary Figure 2). 
As expected, no amplification was visualized both for the 
no template control (NTC) and for SH-SY5Y alone group. 
In contrast, 60% of samples in the GFP only T cell treated 
animals displayed faint bands and 80% of samples from 
the GD2 CAR T cell treated mice revealed a stronger GFP 
signal suggesting a persistence of modified T cells in the 
majority of the treated mice.
Finally, TUNEL assay was introduced to assess the 
degree of apoptosis. Apoptotic cells were sparse in tumor 
specimens of untreated mice as well as in mice treated with 
GFP only T cells (Figure 5B, fourth and fifth row), whereas 
they were clearly visible in the tumor that developed 
in the single mouse of the GD2 CAR treated group 
(Figure 5B, right column). Image-j analyses confirmed 
these observations, and GD2 CAR treated group displayed 
Figure 1: T cells are effectively transduced with GD2 CAR encoding vector. A. The GD2 CAR construct. The IgM derived 
anti-GD2 scFv is linked to the signal transduction domain (STD). B. Replicate samples of anti-GD2 immunized mice sera (M1, M2, M3 and 
M4) efficiently recognize GD2 CAR on FLYRD18 cell surface and are introduced for GD2 CAR detection on transduced T cells. Isotype 
(gray), APC-secondary Ab (broken/gray line) and GD2 positivity (black line). C. GD2 CAR T cells were analysed for both GFP and CAR 
expression levels (48 ± 2% and 40 ± 10%, respectively, p > 0.05 by t-test) while GFP only T cells were exclusively GFP positive (64 ± 5%) 
Mean ± SEM. D. representative phase 1 (Ph1) and green fluorescence (GFP) photomicrographs (scale bar, 50 μm) of non-transduced (NT) 
pre-stimulated T cells (left panel) and GD2 CAR T cells after gene transfer revealing GFP-positive clusters in two representative donors 
(D) in middle (D1) and right (D2) panels.
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Figure 2: Effectors characterization. A. non-transduced T cells (NT), GFP only T cells and GD2 CAR T cell sub-populations 
assessed by flow cytometry: both GFP only T cells and GD2 CAR T cell population was mainly constituted by CD3+/CD8+ cells as well as 
CD3+/CD56+ NK T cells. Data represent mean ± SEM of 5 different donors (p values by t-test). B. representative flow cytometry dot plots 
showing transduced CAR T cell sub-populations.
Figure 3: Target cells characterization. Representative histograms showing GD2 expression (in red) on human SH-SY-5Y and 
SKnBE neuroblastoma cell lines and on HeLa cells, the negative control. APC-conjugated secondary Ab was used as isotype.
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a highly significant increase of apoptosis over SH-SY5Y 
alone and GFP only T cell treated group (Figure 5C).
DISCUSSION
GD2 is overexpressed in neuroblastoma, 
retinoblastoma, melanoma, small-cell lung cancer, 
brain tumors, sarcomas and on discrete breast cancer 
cell sub-populations but it is expressed at low levels 
on normal tissues, therefore representing a target 
for immunotherapy [3, 4]. In this context, anti-GD2 
immunotherapeutic antibodies have been developed and 
anti-GD2 CARs have also been reported [13]. We here 
developed a novel anti-GD2 CAR that, when expressed 
in T lymphocytes, triggers specific anti-tumor activity 
against GD2-positive neuroblastoma cells.
Previous studies showed that a small 
immunoprotein, derived from an IgM (clone 126) and 
including the anti-GD2 scFv of our CAR, retained 
affinity and specificity of the original antibody [12]. 
Therefore, the purpose of this study was to generate a 
second generation CAR by an anti-GD2 scFv-mouse 
IgM capable to conjugate the features of anti-GD2 scFv 
with a potent costimulation driven by 4-1BB molecule. 
Previously, one IgM and two IgG derived anti-GD2 CARs 
were tested against neuroblastoma cells either with or 
without costimulatory signals such as OX40, CD28 and 
4-1BB [14, 15, 16]. In our case and for the first time, 
we selected the anti-GD2 scFv-mouse IgM clone 126 in 
combination with 4-1BB considering the importance of 
this costimulatory molecule to sustain cytotoxic T cell 
activity [17, 18], to favor CD8-positive T cell expansion 
during either viral infection or allograft rejection [19] 
and its crucial role in directing the anti-tumor response 
in animal models and in humans [20]. In particular, an 
anti-CD19 CAR containing 4-1BB signalling has been 
shown to produce dramatic responses in patients with 
B cell malignancies [21].
Our results provided in vitro and in vivo evidences 
of a targeted anti–tumor activity toward GD2-positive 
neuroblastoma cells. Human T lymphocytes were stably 
transduced by retroviral particles revealing significant 
levels (exceeding 50% of GFP positivity) at least in line 
with what was previously reported [16, 22]. The generation 
Figure 4: GD2 CAR T cells exert specific in vitro cytotoxicity. A. 4-hour standard 51Cr release assay. GFP only T cells and GD2 
CAR T cells co-cultured with neuroblastoma cell lines SH-SY5Y, SKnBE or with HeLa cells at E:T ratio of 20:1. B. 4-hour CalceinAM 
viability assay where GFP only T cells and GD2 CAR T cells were co-cultured either with SH-SY5Y or SKnBE cells at E:T ratio of 5:1, 
10:1, 20:1. C. 48-hour co-culture assay with sorted GD2 CAR T cells (85 ± 5% of purity, not shown) co-cultured with SH-SY5Y at E:T 
ratio of 1:1. D. 48-hour co-culture supernatant concentrations of IFNγ and TRAIL measured by ELISA. All data expressed as mean ± SEM 
of at least 3 replicates (p values by t-test).
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of GD2 CAR specific anti-idiotype antibodies allowed us 
to compare the GFP positivity on transduced T cells with 
the real CAR surface expression. Taking advantage of this 
approach, we were able to determine an overlapping signal 
between GFP and GD2 CAR expression that persisted 
for at least 30 days (not shown) after transduction. 
This persistence, when properly translated for clinical 
applications, may be relevant to rapidly evaluate 
transduction levels excluding GFP labelling and its related 
safety concerns after gene modification.
GD2 CAR redirected T cells showed activation, 
proliferation, and cytokine release upon GD2 stimulation. 
We firstly introduced the highest E:T ratio into cytotoxic 
assays in order to identify the most sensitive cell lines. In 
particular, GD2 CAR T cells exhibited specific targeting 
versus SH-SY5Y cells as determined by 51Cr release in 
contrast to GD2-negative HeLa cells and against SKnBE 
neuroblastoma GD2-low expressing cells. Then, the 
viability of selected target cells, SH-SY5Y and SKnBE, 
over different E:T ratio was evaluated by CalceinAM 
4-hour assay which allows to appreciate the specific 
targeting versus SH-SY5Y in all culture conditions. We 
further confirmed the GD2 CAR T cell cytotoxicity versus 
SH-SY5Y cells over 48-hour coculture assay emphasizing 
the impact of sorted CAR positive T cells even when a 
more unfavourable effector to target ratio at 1:1 was 
tested. While we have observed levels of background 
in the 4-hour in vitro cytotoxicity, the addition of CAR 
has been constantly associated with a significant increase 
in killing against SH-SY5Y, the GD2 positive cell line. 
This high background might be due to the existence 
of an alloreactivity that may be even enforced by the 
presence of NK/T (CD3+/CD56+) cells within our effector 
cell sub-populations. However, in the 48-hour assay, 
comparing the sorted CAR population with the GFP only 
T cells, the killing activity background was attenuated 
Figure 5: GD2 CAR T cells provide potent therapeutic activity in a neuroblastoma xenograft. A. GD2 CAR T cells 
were capable of substantially abrogate tumor growth either versus SH-SY5Y treated with parental GFP only T cells or SH-SY5Y alone 
(*p = 0.036, **p = 0.027 by t-test, mean ± SEM). Arrows represent T cell injection time points. T cells were injected locally into the tumor. 
B. representative tumors for each group (first row); representative images of anti-GFP staining (second row with insets) of tumor sections 
obtained from mice injected with SH-SY5Y cells alone (left), SH-SY5Y+GFP only T (middle) or SH-SY5Y+GD2 CAR T cells (right); in 
the fourth row (with insets) TUNEL assay detecting apoptosis. Scale bars: 50 μm and 10 μm for insets. C. fold of increase in apoptosis of 
GD2 CAR T cell treated specimen versus either SH-SY5Y alone or SH-SY5Y treated with GFP only T cells.
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and the difference between the two groups was more 
significantly emerging suggesting the advantage of the 
CAR within a prolonged allogeneic response, as further 
confirmed by cytokine release assay and, even more, by 
the in vivo study.
Curiously, after viral transduction we report a 
proliferation advantage of the NK/T subpopulation in 
transduced T cells versus non-transduced lymphocytes. 
The reasons behind this observation would require further 
investigations. However, it has been reported that the 
RetroNectin (CH-296), used in the gene modification steps, 
may enhance a cytokine-induced killer cell expansion in 
the presence of T cell receptor (TCR)-stimulating signals 
such as IL-2 or IFNγ [23]. Thus, we can hypothesize that 
the presence of both CH-296 and IL-2 during transduction 
could favours the emerging of a NK/T fraction with 
positive impact on CAR T cell therapeutic profile, as 
previously described [24].
Anti-cancer killing activity of CAR resides also 
in cytokines production [16, 25]. We found a significant 
IFNγ release by GD2 CAR T cells over 48-hour cocultures 
with SH-SY5Y. In addition, we observed that GD2 CAR 
T cell action was associated with a dramatic release of 
a potent death ligand, namely TRAIL. Interestingly, 
GFP only T cell counterpart did not show these events 
indicating that CAR expression redirects T cell specificity 
and reprograms their effector functions against responsive 
GD2-positive neuroblastoma cells by producing powerful 
anti-cancer molecules delivered in a combinatory manner.
To evaluate GD2 CAR T cell potential in vivo, a 
subcutaneous neuroblastoma model employing SH-SY5Y 
cells was adopted. Either GD2 CAR T cells or parental 
GFP only T cells were administered at the same dose rate 
to evaluate both antigen specificity and alloreactivity. In 
mice with SH-SY5Y alone a relevant tumor proliferation 
took place similarly to what observed in animals treated 
by allogeneic GFP only T cells. Histology revealed, in the 
GFP only T cell treated mice, tumor-infiltrating elements 
suggesting a sub-optimal alloreactivity occurring in mice 
treated with human T cells. In contrast, GD2 CAR T cells 
had a powerful anti-tumor activity in vivo with a dramatic 
abrogation of tumor growth in all but one animal.
Others reported animal studies of robust 
anti-neuroblastoma activity of CAR anti-GD2 human 
T cells [26, 27], although associated with a xenogenic graft 
versus host disease (GVHD) in a long-term observation 
[26]. In our model, animals were sacrificed at 28 days 
post-injection due to the large size of tumor burden in 
some of the control mice. While comparisons with these 
models may be difficult to implement due to a number 
of variables (i.e. CAR structure, CAR transduction levels, 
gene engineering methods and in vivo study design), we 
confirmed in vivo data without detecting signs of GVHD. 
Further animal studies shall have to be implemented to 
further challenge the model, possibly based on in vivo 
imaging. Nevertheless, histological studies of the unique 
tumor specimens harvested in CAR treated group 
demonstrate that GD2 CAR T cells were able to robustly 
infiltrate tumor site inducing apoptosis suggesting the 
functionality of our approach in vivo.
In this in vivo study, human T cells were also 
revealed in mice blood either in GFP only T cell or in 
GD2 CAR T cell treated animals. While circulating levels 
of these elements appear low, this aspect is of particular 
interest indicating that activated T cells can relocate in 
areas distant from the original intra tumor injection site. 
In addition, while GFP positive circulating T-cells were 
present in both groups, only GD2 CAR T cells were able 
to trigger a significant apoptosis further indicating the 
relevance of this CAR technology leading to the tumor 
abrogation through GD2-specific targeting. More in-depth 
studies are here demanded to better address the dynamic 
of T cell in vivo persistence into blood circulation due 
to the clinical implications of these findings after 
transplantation.
With the limitations of a study performed on 
neuroblastoma cell line only and without comparative 
studies with other anti-neuroblastoma CAR, our strategy 
wanted to propose a novel anti-GD2 CAR able to redirect 
an anti-cancer T cell immune reactivity by-passing tumor 
escape mechanisms that appear to inhibit the simple 
alloreactivity. In summary, we have shown that the IgM 
clone 126-derived GD2 CAR/4-1BB represents a powerful 
tool to empower T cells towards GD2, supporting future 
clinical testing of this therapeutic approach in patients 
with high-risk GD2-positive malignancies.
MATERIALS AND METHODS
Cell lines
SH-SY5Y and SKnBE human neuroblastoma cell 
lines were provided by Pediatric Hospital Gaslini (Genova, 
Italy) and were maintained in DMEM:F12 (Gibco-Life 
Technologies, Grand Islands, NY) supplemented 
with 10% heat-inactivated fetal bovine serum (FBS, 
Gibco-Life Technologies), 1% L-glutamine (200 mmol/L; 
Euroclone, Paignton, UK) and 1% penicillin-streptomycin 
(10000 units penicillin and 10 mg streptomycin/ml in 0.9% 
sodium chloride, Sigma-Aldrich, Ayrshire, UK). 293T 
human embryonic kidney fibroblast cell line and FLYRD18 
packaging cell line (PCL) were cultured as described [28]. 
HeLa human cervix adenocarcinoma cell line (kindly 
provided by Virna Marin, Ospedale S.Gerardo, Monza, 
Italy), used for viral titration and cytotoxicity studies, 
was maintained in complete medium composed by DMEM 
high glucose (Euroclone) with 10% heat-inactivated fetal 
bovine serum, and 1% penicillin-streptomycin. Tumor cell 
line authentication was performed by DNA profiling using 
8 different and highly polymorphic short tandem repeat 




Peripheral blood mononuclear cells (PBMC) were 
separated by density gradient from the peripheral blood 
of healthy donors after informed consent (Lymphoprep; 
Fresenius, Axis-Shield, Oslo, Norway) and then plated 
in RPMI 1640 with 1% FBS, 1% glutamine and 1% 
penicillin-streptomycin. Non-adherent cells were 
collected and pre-stimulated for 48 hours in RPMI 1640 
supplemented with 10% heat-inactivated defined FBS, 
500 UI/mL rhInterleukin-2 (rhIL-2, Proleukin, Novartis 
Farma S.p.a) and 7 μg/mL Phytohemagglutinin (PHA-M, 
Sigma-Aldrich) at the concentration of 1 × 106 cells/mL.
Chimeric antigen receptor construct and vectors
The anti-GD2 mouse heavy (VH) and light 
(VL) encoding sequences, derived from the IgM 
producer hybridoma 126, were previously inserted 
in the expression vector pcDNA3 generating the 
pcDNA3-GD2-hεSIP plasmid [12]. The cDNA 
encoding for the anti-GD2 scFv was then isolated 
by PCR using gene specific primers: forward 
5′-CAGATCTGATGGGCTGGAGCCTGATCCT -3′ and 
rev 5′TGGCGTCGTGGTAGAGACAGTGACCAG-3′. 
The signal transduction domain (STD), encoding for 
the human CD8α hinge-transmembrane domain as 
well as for a portion of the human 4-1BB molecule 
and CD3 ζ endodomain, was subcloned from an 
anti-CD19–41BB-CD3ζ CAR developed at St Jude 
Children’s Research Hospital (Memphis, TN) [17] 
using the following primers: for 5′-GTCACTGTCTCT 
ACCACGACGCCAGCGCCG-3′ and rev 
5′GGAATTCCTGTGTCTCATAATCTGGGCGTC-3′. 
The scFv region was subsequently joined to the STD 
by splicing overlapping extension PCR (SOE-PCR) 
technique [29] and cloned by TOPO TA Cloning Kit 
(Invitrogen, Paisley, UK). The whole cDNA encoding 
for the anti-GD2-BB-ζ CAR was then confirmed 
by direct sequencing with ABIprism 3100 Genetic 
Analyzer (Applied Biosystems, Foster City, CA, USA) 
and the anti-GD2-BB-ζ CAR expression cassette 
was subcloned into the multiple cloning site of the 
pMIGR1-IRES-GFP retroviral vector, using BgIII and 
EcoRI restriction enzymes as described [29] obtaining a 
pMIGR1-anti-GD2-BB-ζ retroviral vector (GD2 CAR). 
pMIGR1 vector expressing GFP (GFP only) was used as 
a control.
Recombinant retrovirus production  
and gene transfer
Helper plasmids, pSRαG encoding for the Vesicular 
Stomatitis Virus (VSV-G) envelope glycoprotein and 
pMDL encoding for gag-pol genes, were mixed to the 
respective vector plasmid pMIGR1-anti-GD2-BB-ζ and 
pMIGR1-IRES-GFP and employed to produce transiently 
transfected 293T cells as described [28].
To generate stable retrovirus producer cell lines, 
retroviral supernatants were collected 48 hours after 293T 
transfection and used to infect the FLYRD18 packaging 
cell line by overnight incubation at 37°C in the presence 
of polybrene (6 μg/mL; Sigma-Aldrich). Retroviral 
supernatants were generated from the FLYRD18 cell 
line in DMEM supplemented with 10% defined FBS. 
After 24 hours of incubation at 37°C the supernatants 
were filtered (0.45 μm PES filter), titrated on HeLa 
cells and finally employed to transduce pre-stimulated 
T lymphocytes. Pre-stimulated T cells were transduced 
by either pMIGR1-anti-GD2–41BB-CD3ζ CAR 
(“GD2 CAR”) or pMIGR1-IRES-GFP (“GFP only”) 
retroviral supernatants in the presence of polybrene 
(4 μg/mL; Sigma-Aldrich) in RetroNectin-coated tubes 
(rh fibronectin fragment CH-296, Takara Bio, Shiga, 
Japan) over 6-hour of incubation, for 3 consecutive 
days. Transduced T cells were then expanded at the 
concentration of 1 × 106/mL in RPMI 1640 supplemented 
with 10% heat-inactivated defined FBS, 500 UI/mL rhIL-2 
and magnetic beads coated with anti-CD3 and anti-CD28 
antibodies (Life Technologies) at 3:1 ratio to T cell.
Flow cytometry
To assess the immunophenotype, T cells 
were stained with a panel of dye-conjugated mouse 
anti-human monoclonal antibodies CD3-PE/APC, 
CD4-APC, CD8-APC, CD16-PE, CD56-APC and 
CD45-PE/APC (Becton Dickinson-BD, San Jose, 
CA). To evaluate GD2 antigen expression, tumor cell 
lines were stained with a primary unconjugated mouse 
anti-human Disialoganglioside GD2 (BD) and then 
with APC-conjugated goat anti-mouse Ig (APC Goat 
Anti-Mouse Ig polyclonal multiple adsorption; BD). All 
samples were acquired by BD FACSAria III (BD, Franklin 
Lakes, NJ), and analysed using BD FACSDiva software. 
GD2 CAR enriched T cell population was achieved by cell 
sorting gating on GFP-positive cells.
Anti-idiotypic antibody production
To detect GD2 CAR expression in T cells, 
anti-idiotypic antibodies were raised as described [30]. 
BALB/c mice (n = 4) were genetically immunized 
intradermally by biolistic gold particles coated with the 
plasmid pcDNA3-GD2-hεSIP coding for the MoAb 
126-derived anti-GD2 scFv in the form of a Small 
Immunoprotein (SIP) [12], using the Gene Gun device 
(BioRad, Hercules, CA). Three biweekly deliveries for 
each mouse were performed. Sera from immunized mice 
were collected 10 days after the last immunization and 
titrated by flow cytometry for anti-idiotypic antibodies 
on FLYRD18 packaging cell line expressing GD2 CAR. 
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CAR expression in transduced T cells was tested by 
anti-idiotype mice sera followed by APC-conjugated goat 
anti-mouse Ig secondary antibody (BD Pharmingen). 
T cells were then analysed for both GFP and CAR 
expression by flow cytometry.
Cytotoxicity assays
The cytotoxic activity of GD2 CAR and GFP only 
T cells was tested in a standard 4-hour 51Cr release assay 
as previously described [31]. Isotope release after 4 hour 
cocultures with effector-to-target (E:T) ratio of 20:1 
was assessed by 2450 microplate counter MicroBeta2TM 
(Perkin-Elmer). Target cells (SH-SY5Y, SKnBE and 
HeLa) were incubated either in complete medium 
alone or in 1% Triton X-100 (Sigma) to determine the 
spontaneous and the maximum 51Cr release, respectively. 
Mean percentage of triplicate specific lysis wells was 
calculated as 100 x (experimental release - spontaneous 
release)/(maximal release - spontaneous release). Target 
cell viability was additionally evaluated by a 4-hour 
calceinAM assay [32]. Target cells (SH-SY5Y and 
SKnBE) were labeled with calceinAM and cocultured 
at E:T ratio of 5:1, 10:1 and 20:1. Cultures containing 
medium alone or 1% Triton X-100 were used as controls, 
representing 100% and 0% cell viability, respectively. 
Average viability was calculated as 100 x (experimental 
fluorescence - 0% viability fluorescence)/(100% viability 
fluorescence - 0% viability fluorescence). Samples 
were measured using Victor3 multilabel plate reader 
(PerkinElmer, Waltham, MA, USA).
The anti-tumor activity of GD2 CAR T cells after 
GFP sorting was validated in 48-hour assays. SH-SY5Y 
cells were seeded at E:T ratio of 1:1 with either GFP only 
T cells or GD2 CAR T cells in RPMI supplemented with 
10% FBS, 500 UI/mL rhIL-2 and incubated for 48 hours. 
Cells were then harvested and stained by both anti-GD2 
and anti-CD45 MoAbs specifically identifying target and 
T cells, respectively. The cytotoxic impact of T cells over 
48-hour cocultures was assessed by FACS evaluating 
persistent CD45-negative/GD2-positive cells and was 
represented as percentage of lysis.
ELISA
Interferon gamma (IFNγ) and tumor necrosis 
factor related apoptosis inducing ligand (TRAIL) levels 
were measured in supernatants from 48-hour coculture 
assays, using either Human IFNγ ELISA Kit (Boster 
immunoleader, Fremont, CA) and Human TRAIL kit assay 
(R&D System Inc, Minneapolis, MN).
Xenotransplant models
To assess in vivo anti–tumor activity of GD2 
CAR T cells, we generated NOD/SCID mouse model 
(NOD.C.B-17-Prkdcscid/J, Charles River Laboratories 
Italia, SRL, Lecco, Italy) selecting the human SH-
SY5Y neuroblastoma cell line as target. Twelve week 
old mice, six per group, were subcutaneously injected 
into the flank at day 0 with 1 × 106 SH-SY5Y cells 
suspended in 0.2 mL Matrigel (BD Biosciences) and at 
day 0, 7 and 14, either GFP only T cells or GD2 CAR 
T cells (5 × 106/each time point) were locally injected. 
Mice were given intraperitoneal injection of 1000 UI/
mouse of rhIL-2 (Proleukin, Novartis) once a week. 
Animal weight and mass growth were monitored till the 
end of the in vivo study at day 28. Longest length and 
width measurements were recorded and tumor volume was 
calculated according to the formula (length*width2/2). All 
mouse experiments were done with approval of the local 
Institutional Animal Care and Use Committee overseeing 
animal experimentation.
Histology and TUNEL
Formalin-fixed, paraffin-embedded tumor 
specimens were cut and stained by hematoxylin-and-eosin 
staining (Sigma-Aldrich, St Louis, MO). To detect 
GFP-positive cells, sections were retrieved in citrate 
buffer (pH 6) for 15 minutes. Primary rabbit polyclonal 
anti-GFP antibody (1:1200; Abcam: ab290-50) was 
incubated overnight at 4°C. Slides were then incubated 
with biotinylated goat anti-rabbit IgG (H+L) (1:200; 
Vector Laboratories, Burlingame, CA) for 1 hour at room 
temperature. Negative controls were run simultaneously 
by omitting primary antibody while incubating 
with buffer. GFP-positive cells were visualized by 
diaminobenzidine (DAB, Vector Laboratories). All slides 
were counterstained with Harris hematoxylin (Bio Optica, 
Milan, Italy). Sections were examined by Zeiss Axioskop 
(Zeiss, Oberkochen, Germany). Photomicrographs were 
acquired by AxioCam ICc3 color camera and AxioVision 
software (Zeiss). GFP analysis was performed by 
ImageJ (NIH, Bethesda, MD). TUNEL staining was 
performed by using Tumor TACS™ In Situ Apoptosis 
Detection Kit (Trevigen, Gaithersburg, MD). Briefly, 
after deparaffinization and rehydration, specimens were 
treated with proteinase K solution and quenched with 3% 
hydrogen peroxide solution. The 3′ ends of cleaved DNA 
fragments in apoptotic cells are recognized by the terminal 
deoxynucleotidyl transferase for the incorporation of 
biotinylated nucleotides. Visualization of chromosomal 
DNA fragments was allowed by binding of streptavidin-
HRP and subsequent DAB incubation. As positive control 
for apoptosis detection, one section was treated with 
nuclease to induce DNA fragmentation; TdT enzyme was 
omitted as a negative control. A nuclear counterstain was 
performed with methyl green. Sections were examined 
by Zeiss Axioskop (Zeiss, Oberkochen, Germany). 
Photomicrographs were acquired by AxioCam ICc3 color 
camera and AxioVision software (Zeiss).
Oncotarget10www.impactjournals.com/oncotarget
Statistics
All in vitro and in vivo data are expressed by 
means and SEM. Paired Student’s t test was used to 
determine statistical significance. P < 0.05 was considered 
statistically significant.
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